EX-99.1 2 d126052dex991.htm EX-99.1 EX-99.1

Exhibit 1

Joint Filing Agreement

The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Shares of LAVA Therapeutics N.V. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D.

April 8, 2021

 

Versant Venture Capital VI, L.P.

By:

  

Versant Ventures VI GP, L.P.

Its:

  

General Partner

By:

  

Versant Ventures VI GP-GP, LLC

Its:

  

General Partner

By:   /s/ Robin L. Praeger, Managing Director

Versant Ventures VI GP, L.P.

By:

  

Versant Ventures VI GP-GP, LLC

Its:

  

General Partner

By:   /s/ Robin L. Praeger, Managing Director

Versant Ventures VI GP-GP, LLC

By:   /s/ Robin L. Praeger, Managing Director

Versant Vantage I, L.P.

By:

  

Versant Vantage I GP, L.P.

Its:

  

General Partner

By:

  

Versant Vantage I GP-GP, LLC

Its:

  

General Partner

By:   /s/ Robin L. Praeger, Managing Director

Versant Vantage I GP, L.P.

By:

  

Versant Vantage I GP-GP, LLC

Its:

  

General Partner

By:   /s/ Robin L. Praeger, Managing Director

Versant Vantage I GP-GP, LLC

By:   /s/ Robin L. Praeger, Managing Director